Trial Profile

Study of IGM-2644 in generalized myasthenia gravis patients

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 16 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IGM-2644 (Primary)
Indications Myasthenia gravis
Focus Adverse reactions

Most Recent Events

09 Jan 2025 Status changed from planning to discontinued (due to strategic considerations), according to an IGM Biosciences media release.
21 Aug 2024 New trial record
14 Aug 2024 According to an IGM Biosciences media release, The Company currently expects to begin enrolling patients in a single arm, open-label clinical study testing IGM-2644 in generalized myasthenia gravis (gMG) by the end of 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com